BELLICUM PHARMACEUTICALS INC's ticker is BLCM and the CUSIP is 079481107. A total of 94 filers reported holding BELLICUM PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $129,000 | +7.5% | 38,200 | -7.1% | 0.00% | – |
| Q4 2018 | $120,000 | -52.6% | 41,100 | 0.0% | 0.00% | – |
| Q3 2018 | $253,000 | -7.7% | 41,100 | +10.8% | 0.00% | – |
| Q2 2018 | $274,000 | +25.7% | 37,100 | +11.7% | 0.00% | – |
| Q1 2018 | $218,000 | -21.9% | 33,200 | 0.0% | 0.00% | – |
| Q4 2017 | $279,000 | -27.2% | 33,200 | 0.0% | 0.00% | – |
| Q3 2017 | $383,000 | -1.3% | 33,200 | 0.0% | 0.00% | – |
| Q2 2017 | $388,000 | +62.3% | 33,200 | +71.1% | 0.00% | – |
| Q1 2017 | $239,000 | -9.5% | 19,400 | 0.0% | 0.00% | – |
| Q4 2016 | $264,000 | -31.6% | 19,400 | 0.0% | 0.00% | – |
| Q3 2016 | $386,000 | +53.8% | 19,400 | 0.0% | 0.00% | – |
| Q2 2016 | $251,000 | +71.9% | 19,400 | +24.4% | 0.00% | – |
| Q1 2016 | $146,000 | -63.2% | 15,600 | -20.4% | 0.00% | – |
| Q4 2015 | $397,000 | +65.4% | 19,600 | +18.8% | 0.00% | – |
| Q3 2015 | $240,000 | -17.0% | 16,500 | +21.3% | 0.00% | – |
| Q2 2015 | $289,000 | – | 13,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Virtus ETF Advisers LLC | 15,086 | $306,000 | 0.84% |
| Baker Brothers Advisors | 4,865,647 | $98,627,000 | 0.82% |
| Cormorant Asset Management, LP | 300,000 | $6,081,000 | 0.73% |
| SPHERA FUNDS MANAGEMENT LTD. | 231,515 | $4,693,000 | 0.69% |
| QVT Financial LP | 340,986 | $6,912,000 | 0.39% |
| Graticule Asia Macro Advisors LLC | 87,000 | $1,763,000 | 0.29% |
| Hatteras Investment Partners, LP | 10,410 | $211,000 | 0.28% |
| MCDANIEL TERRY & CO | 33,836 | $686,000 | 0.18% |
| Highlander Capital Management, LLC | 6,500 | $132,000 | 0.12% |
| EverPoint Asset Management, LLC | 265,000 | $5,372,000 | 0.11% |